loadpatents
Patent applications and USPTO patent grants for Dixit; Vishva.The latest application filed is for "anti-polyubiquitin multispecific antibodies".
Patent | Date |
---|---|
Anti-Polyubiquitin Multispecific Antibodies App 20220242938 - Dixit; Vishva ;   et al. | 2022-08-04 |
Anti-polyubiquitin multispecific antibodies Grant 11,274,145 - Dixit , et al. March 15, 2 | 2022-03-15 |
Anti-Polyubiquitin Antibodies and Methods of Use App 20210340234 - Dixit; Vishva ;   et al. | 2021-11-04 |
Anti-polyubiquitin antibodies and methods of use Grant 11,066,463 - Dixit , et al. July 20, 2 | 2021-07-20 |
Anti-Polyubiquitin Antibodies App 20210017260 - Kelley; Robert F. ;   et al. | 2021-01-21 |
Nucleic acids encoding anti-polyubiquitin antibodies Grant 10,738,106 - Kelley , et al. A | 2020-08-11 |
Anti-Polyubiquitin Multispecific Antibodies App 20190169278 - Dixit; Vishva ;   et al. | 2019-06-06 |
Anti-Polyubiquitin Antibodies and Methods of Use App 20190100578 - Dixit; Vishva ;   et al. | 2019-04-04 |
Anti-polyubiquitin antibodies and methods of use Grant 10,100,105 - Dixit , et al. October 16, 2 | 2018-10-16 |
Anti-polyubiquitin Antibodies And Methods Of Use App 20170240620 - Dixit; Vishva ;   et al. | 2017-08-24 |
Anti-polyubiquitin antibodies and methods of use Grant 9,556,262 - Dixit , et al. January 31, 2 | 2017-01-31 |
Anti-polyubiquitin Antibodies App 20160304591 - Kelley; Robert F. ;   et al. | 2016-10-20 |
Anti-polyubiquitin antibodies Grant 9,321,844 - Kelley , et al. April 26, 2 | 2016-04-26 |
Anti-polyubiquitin Antibodies And Methods Of Use App 20150307602 - Dixit; Vishva ;   et al. | 2015-10-29 |
Anti-polyubiquitin antibodies and methods of use Grant 8,992,919 - Dixit , et al. March 31, 2 | 2015-03-31 |
Anti-polyubiquitin Antibodies And Methods Of Use App 20130058955 - Kelley; Robert F. ;   et al. | 2013-03-07 |
Anti-polyubiquitin Antibodies And Methods Of Use App 20110256133 - DIXIT; VISHVA ;   et al. | 2011-10-20 |
Copi Molecules And Uses Thereof App 20110045474 - Dornan; David ;   et al. | 2011-02-24 |
COP1 molecules and uses thereof Grant 7,785,815 - Dornan , et al. August 31, 2 | 2010-08-31 |
Methods for making recombinant proteins using apoptosis inhibitors App 20100087624 - Dixit; Vishva ;   et al. | 2010-04-08 |
Methods And Compositions For Targeting Relt App 20080057066 - Dixit; Vishva ;   et al. | 2008-03-06 |
COP1 molecules and uses thereof App 20080009458 - Dornan; David ;   et al. | 2008-01-10 |
Methods for making recombinant proteins using apoptosis inhibitors App 20070004009 - Dixit; Vishva ;   et al. | 2007-01-04 |
Death domain containing receptors Grant 6,951,735 - Yu , et al. October 4, 2 | 2005-10-04 |
Taci and br3 polypeptides and uses thereof App 20050070689 - Dixit, Vishva ;   et al. | 2005-03-31 |
Methods for making recombinant proteins using apoptosis inhibitors App 20040002139 - Dixit, Vishva ;   et al. | 2004-01-01 |
Methods for making recombinant proteins using apoptosis inhibitors Grant 6,586,206 - Dixit , et al. July 1, 2 | 2003-07-01 |
Death Domain Containing Receptors App 20030077694 - YU, GUO-LIANG ;   et al. | 2003-04-24 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.